CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 156 enrolled
Drug / intervention
PyroTITAN HRAdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02405208
NCT02405208N/ACompleted
CompareCT.gov

A Multi-center Outcomes Clinical Study of the PyroTITAN™ HRA Shoulder Implant in Humeral Head Resurfacing

Smith & Nephew, Inc.·observational·Posted Apr 1, 2015·Updated Dec 24, 2025

In Brief

An observational study evaluating PyroTITAN HRA for Arthritis. Completed, enrolled 156 participants across 5 sites in 4 countries.

Detailed Summary

This study is designed as a multi-center, nonrandomized, uncontrolled, unblinded, prospective clinical outcomes investigation to evaluate the short, mid and long term performance of the PyroTITAN™ HRA Shoulder prosthesis humeral replacement.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsArthritis
CountriesAustralia, France, Sweden, United Kingdom
Collaborators--

Timeline

N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedApr 1, 2015
Enrollment StartAug 1, 2010
Primary CompletionSep 1, 2023
TodayJul 2, 2026
Enrollment to primary: 13.1 yearsPosted 11.3 years ago

Interventions

PyroTITAN HRAdevice

Humeral resurfacing using the PyroTITAN HRA device